Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies

Authors

David Siegel, John Theurer Cancer Center
Thomas Martin, University of California - San Francisco
Ajay Nooka, Winship Cancer Institute of Emory University
R. Donald Harvey, Winship Cancer Institute of Emory University
Ravi Vij, Washington University School of Medicine in St. Louis
Ruben Niesvizky, Weill Cornell Medical College
Ashraf Z. Badros, University of Maryland - Baltimore
Sundar Jagannath, Mount Sinai Medical Center
Leanne McCulloch, Onyx Pharmaceuticals Inc.
Kanya Rajangam, Onyx Pharmaceuticals Inc.
Sagar Lonial, Winship Cancer Institute of Emory University

Journal

Haematologica

Publication Date

2013

Volume

98

Issue

11

Inclusive Pages

1753-1761

Document Type

Open Access Publication

DOI

10.3324/haematol.2013.089334

Rights and Permissions

David Siegel, et al. (2013) Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies. Haematologica 98(11):1753-1761. doi:10.3324/haematol.2013.089334. Obtained from the Haematologica Journal website http://www.haematologica.org

Recommended Citation

Siegel, David; Martin, Thomas; Nooka, Ajay; Harvey, R. Donald; Vij, Ravi; Niesvizky, Ruben; Badros, Ashraf Z.; Jagannath, Sundar; McCulloch, Leanne; Rajangam, Kanya; and Lonial, Sagar, "Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies." Haematologica. 98, 11. 1753-1761. (2013).
https://digitalcommons.wustl.edu/open_access_pubs/4226